Increased TRPM2 in tumors may be both a driver of high FOXM1 and the embryonic stem cell program seen in non-MYCN amplified Stage 4 neuroblastoma patients, contributing to increased metastasis and worse outcome43. Here, FOXM1 is linked to neuroblastoma.